Home / Reports

Reports

Is China set to lose its low-cost appeal?

Over the last few years, with rising costs in Europe and the US, Western pharmaceutical companies have increasingly looked to outsource manufacturing to low-cost countries like China. However, inflation, rising costs and wage increases may change all this.

Opportunities in the COPD market

The increasing elderly population and increases in diagnosis and drug treatment will fuel a steady 4.6% annual growth in the chronic obstructive pulmonary disease (COPD) drug market, says a new report.

More drug recalls due to poor manufacturing

The quality of raw materials and contamination is under scrutiny by the FDA once again as Indian generics’ manufacturer Sun Pharmaceutical Industries Ltd is cited for manufacturing violations.

Opportunities for generic inhalation and nasal spray drugs

A new report from Espicom’s Senior Market Analyst, Mrs Karen Holmes, discusses emerging opportunities for inhalation and nasal spray drugs. It reviews currently available generic products and assesses the prospects for originator drugs losing patent protection over the next 10 years.

MSD-Chibret signs generics deal with French manufacturer

On 25 June 2010 Merck Sharp & Dohme-Chibret (MSD-Chibret) signed an agreement with subcontractor Fareva under an incentive set up by the strategic council of health industries (Csis) meeting, aimed at keeping pharmaceutical production in France.

Italy to scrap tender system to boost generic volumes

On 23 June 2010, the Italian Health Minister, Mr Ferruccio Fazio, announced that Italy has decided to scrap its plans to introduce a new tendering system for reimbursable off-patent medicines in favour of measures to boost generic volumes.

Opportunities arising from increased use of generics

Ensuring the sustainability of the generic medicines industry is one of the key elements in maintaining broad access to medicines for all. To meet increasing demand from more patients who are living longer and expecting an improved quality of life, generic medicines offer quality treatment at affordable prices.

Challenges facing generic manufacturers in Europe

There are many challenges that may limit the competitiveness and sustainability of the European generics sector. Costs and pricing, especially in light of recent cost-cutting exercises in many European countries, is seen as one of the most important. However, limitations on pre-empting patent expiry, increasingly stringent regulations and the effect of tendering also have an impact.

The role of generic medicines in Europe

The role of generic medicines has been to provide essential medicines that are both high quality and affordable throughout the EU. They have enabled increased access to medicines for patients and provided significant savings for EU healthcare systems.

The rising cost of health care in Europe

The ageing population and lifestyle changes bring an increased burden on health care and consequently an increase in costs. This growing cost of health care is unavoidable, and drug expenditure is forecast to increase by around 5% annually over the next 3–5 years. Increased use of generics could, however, help to offset some of this increase.